{"paperId": "bf87ac2247a694963cc88410ee2c4bf2c3512eb8", "publicationVenue": {"id": "b584320a-9e3c-4c68-a677-a15f68472cb6", "name": "Alimentary Pharmacology and Therapeutics", "type": "journal", "alternate_names": ["Aliment Pharmacol Ther", "Aliment Pharmacol  Ther", "Alimentary Pharmacology & Therapeutics"], "issn": "0269-2813", "url": "http://www3.interscience.wiley.com/journal/117987555/home", "alternate_urls": ["https://onlinelibrary.wiley.com/journal/13652036"]}, "title": "Review article: randomised controlled trials in inflammatory bowel disease\u2014common challenges and potential solutions", "abstract": "Recruitment rates for Crohn\u2019s disease and ulcerative colitis clinical trials continue to decrease annually. The inability to reach recruitment targets and complete trials has serious implications for stakeholders in the inflammatory bowel disease (IBD) community. Action is required to ensure patients with an unmet medical need have access to new therapies to improve the management of their IBD.", "venue": "Alimentary Pharmacology and Therapeutics", "year": 2022, "fieldsOfStudy": ["Medicine"], "publicationTypes": ["JournalArticle", "Review"], "publicationDate": "2022-02-07", "journal": {"name": "Alimentary Pharmacology & Therapeutics", "pages": "658 - 669", "volume": "55"}, "authors": [{"authorId": "2057440240", "name": "S. Schreiber"}, {"authorId": "144324915", "name": "P. Irving"}, {"authorId": "5563009", "name": "A. Sharara"}, {"authorId": "1402536426", "name": "M. Mart\u00edn-Arranz"}, {"authorId": "3736388", "name": "X. H\u00e9buterne"}, {"authorId": "39863073", "name": "P. Penchev"}, {"authorId": "2379943", "name": "S. Danese"}, {"authorId": "5732748", "name": "P. Anthopoulos"}, {"authorId": "1421515114", "name": "Gamar Akhundova-Unadkat"}, {"authorId": "4107775", "name": "F. Baert"}], "citations": [{"paperId": "5261ed6ffa8ce0a61db5221ecc5c7a7721f4bed0", "title": "Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn\u00b4s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity"}, {"paperId": "60810f2441ea2306cd2a687de5bc27902e1ada6a", "title": "Review article: Externally derived control arms\u2014An opportunity for clinical trials in inflammatory bowel disease?"}, {"paperId": "7c4697f50fb9a7720940811c88672b636ab3bcd5", "title": "Surfing the web as a patient with IBD: New horizons"}, {"paperId": "69d2966d19dbe58a241eb5fe88c8d306625e58e9", "title": "Promising phase II biologics for future Crohn\u2019s disease therapy"}, {"paperId": "8d6a4c7b0b98daa55ed645aa6324b72f94cd5fec", "title": "Crossing barriers: the burden of inflammatory bowel disease across Western Europe"}, {"paperId": "df26cde16cd6476ce867ae7092daac8bc3d2a150", "title": "Partially randomised, patient preference trials for inflammatory bowel disease."}]}
